Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Key facts

Sponsor

NYU Langone Health

Principal Investigator

Peter Izmirly

NYU Langone Health

Intervention

Hydroxychloroquine(drug)

Enrollment

330 target

Eligibility

60 years · All sexes

Timeline

2024 – 2029

Study locations (10)

• University of California, Los Angeles, Los Angeles, California, United States
• Hackensack Meridian Health, Hackensack, New Jersey, United States
• VA NY Harbor Healthcare System, New York, New York, United States
• NYC Health + Hospitals/Bellevue, New York, New York, United States
• NYU Langone Health, New York, New York, United States
• Hospital for Special Surgery, New York, New York, United States
• Columbia University Irving Medical Center/New York Presbyterian, New York, New York, United States
• Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx, New York, United States
• Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
• Penn State MS Hershey Medical Center, Hershey, Pennsylvania, United States

Collaborators

National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07425730
  Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus
  Shanghai Jiao Tong University School of Medicine
• RECRUITINGEARLY PHASE1NCT07339332
  A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGPHASE1NCT07109986
  UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
  Nanjing IASO Biotechnology Co., Ltd.
• ACTIVE NOT RECRUITINGNANCT07196072
  A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic Pain
  University of Michigan
• RECRUITINGNCT07128966
  Direct to Patient Minimal Risk Biospecimen and Data Collection Research
  Joined Bio
• RECRUITINGNCT06659029
  Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
  AstraZeneca
• RECRUITINGPHASE1NCT06613360
  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
  Cullinan Therapeutics Inc.
• RECRUITINGNCT07017868
  Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
  Sohag University

See all trials for Pediatric systemic lupus erythematosus →